What is the overall conclusion about empiric zinc therapy for childhood diarrhea in low-income countries?

• A. It significantly reduces stool output and duration.
• B. The bulk of evidence supports zinc therapy, reducing duration, hospitalizations, and mortality.
• C. There is no clear evidence of benefit.
• D. Zinc therapy increases the risk of diarrheal mortality.

Answer: (B)

Zinc supports intestinal repair and immune function, so giving it during a diarrheal illness helps the body recover faster. In many randomized trials conducted in low-income settings, empiric zinc therapy for acute childhood diarrhea consistently reduces how long the illness lasts, lowers stool output, and lessens the risk of persistent diarrhea. Importantly, it also lowers hospitalizations and mortality in this population. Because these benefits are repeatedly seen across diverse studies, zinc supplementation is regarded as a beneficial standard approach for managing childhood diarrhea in resource-llimited countries. It’s also inexpensive, safe, and easy to administer, which strengthens its public health impact.